Suenaga M
Dept. of Surgery, Nagoya Memorial Hospital.
Gan No Rinsho. 1988 May;34(6):744-8.
Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg). The maximum 5-FU value was found to be 3.45 +/- 3.21 micrograms/ml (n = 22) at 2 hours, and this value decreased linearly. The concentrations of 5-FU in the liver tissues were 0.02 +/- 0.01 micrograms/g (n = 16) and the concentrations of 5-FU in cancer tissues were 0.03 +/- 0.01 micrograms/g (n = 16). There were no statistical differences found between cirrhotic patients and non-cirrhotic patients. These results indicate that the concentrations of HCFU in the serum and tissues were not influenced by liver damage.
在对患者进行肝细胞癌(HCC)切除术前,口服1 - 己基氨基甲酰基 - 5 - 氟尿嘧啶(HCFU,300mg)后,测定了血清、肝脏及癌组织中5 - 氟尿嘧啶(5 - FU)和1 - 己基氨基甲酰基 - 5 - 氟尿嘧啶(HCFU)的浓度。发现5 - FU的最高值在2小时时为3.45±3.21微克/毫升(n = 22),且该值呈线性下降。肝组织中5 - FU的浓度为0.02±0.01微克/克(n = 16),癌组织中5 - FU的浓度为0.03±0.01微克/克(n = 16)。肝硬化患者和非肝硬化患者之间未发现统计学差异。这些结果表明,血清和组织中HCFU的浓度不受肝损伤的影响。